Ravulizumab-Cwvz
Brand name: Ultomiris
Rank #397 of 500 drugs by total cost
$23.1M
Total Cost
428
Total Claims
$23.1M
Total Cost
17
Prescribers
$54K
Cost per Claim
0
Beneficiaries
633
30-Day Fills
$1.4M
Avg Cost/Provider
25
Avg Claims/Provider
About Ravulizumab-Cwvz
Ravulizumab-Cwvz (sold as Ultomiris) was prescribed 428 times by 17 Medicare Part D providers in 2023, costing the program $23.1M. At $54K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 394 | Siponimod (Mayzent) | $23.5M | 2,195 |
| 395 | Droxidopa (Droxidopa) | $23.4M | 9,058 |
| 396 | Fenofibrate Nanocrystallized (Fenofibrate) | $23.2M | 602,181 |
| 397 | Ravulizumab-Cwvz (Ultomiris) | $23.1M | 428 |
| 398 | Roflumilast (Roflumilast) | $22.8M | 97,022 |
| 399 | Romosozumab-Aqqg (Evenity (2 Syringes)) | $22.3M | 9,087 |
| 400 | Azithromycin (Azithromycin) | $22.2M | 3,009,458 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology